Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight

According to DelveInsight's' estimates, the liver cirrhosis market in the 7MM is expected to show positive growth, during the forecast period (2023–2032), mainly attributed to the launch of upcoming therapies and the increasing prevalence of the liver cirrhosis

LAS VEGAS, July 12, 2023 /PRNewswire/ -- DelveInsight's Liver Cirrhosis Market Insights report includes a comprehensive understanding of current treatment practices, liver cirrhosis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].

Key Takeaways from the Liver Cirrhosis Market Report

• As per DelveInsight analysis, the liver cirrhosis market size in the 7MM was approximately USD 3 billion in 2022.
• According to the assessment done by DelveInsight, the estimated total diagnosed prevalent liver cirrhosis cases in the 7MM were approximately 3.4 million in 2022.
• Leading liver cirrhosis companies such as Madrigal Pharmaceuticals, Inc., Galectin Therapeutics Inc., Grifols Therapeutics LLC, CymaBay Therapeutics, Akero Therapeutics, Inc., NGM Biopharmaceuticals, Inc., Gilead Sciences, Novo Nordisk A/S, Cellaion/Promethera Therapeutics, Lipocine Inc., Bristol Myers Squibb, Prism Pharma/Ohara Pharmaceutical, Shionogi/Rohto, and others are developing novel liver cirrhosis drugs that can be available in the liver cirrhosis market in the coming years.
• The promising liver cirrhosis therapies in the pipeline include Resmetirom (MGL-3196), Belapectin (GR-MD-02), Albutein, Seladelpar, Efruxifermin (AKR-001), Aldafermin (NGM282), Semaglutide, Cilofexor, and Firsocostat, Semaglutide, NNC0194-0499, HepaStem, LPCN 1148, BMS-986263, PRI-724, ADR-001, and others.

Discover which therapies are expected to grab the major liver cirrhosis market share @ Liver Cirrhosis Market Report

Liver Cirrhosis Overview

Liver cirrhosis is a disease that causes a hardening of the organ. Nodules and abnormalities form on both the inside and outside of the liver, and these changes can be discovered with an ultrasonic examination or a CT scan. Because liver function steadily declines, liver cirrhosis frequently goes unreported and unacknowledged. As a result, it is critical to have regular examinations. Cirrhosis is most commonly caused by hepatitis C virus (HCV), alcoholic liver disease, and nonalcoholic steatohepatitis (NASH) in the developed world, whereas hepatitis B virus (HBV) and HCV are the most common causes in the developing world. Cirrhosis can be caused by autoimmune hepatitis, primary biliary cholangitis, primary sclerosing cholangitis, hemochromatosis, Wilson disease, alpha-1 antitrypsin deficiency, Budd-Chiari syndrome, drug-induced liver cirrhosis, and chronic right-sided heart failure, and others. The appearance of symptoms determines the classification of liver cirrhosis: liver cirrhosis that results in obvious symptoms such as jaundice, ascites, and hepatic encephalopathy is called decompensated cirrhosis, whereas liver cirrhosis that does not produce these symptoms is called compensated cirrhosis.

Liver Cirrhosis Epidemiology Segmentation

DelveInsight estimates that there were approximately 3.4 million diagnosed prevalent cases of liver cirrhosis in the 7MM in 2022.

The US consistently showed to have the highest diagnosed prevalent cases of liver cirrhosis with nearly 2.1 million cases in 2022 among 7MM. As per DelveInsight's estimates, the country alone accounts for nearly 61% of total diagnosed prevalent cases of liver cirrhosis in the 7MM, followed by Japan, contributing 15% of all liver cirrhosis cases.

The liver cirrhosis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

• Total Liver Cirrhosis Diagnosed Prevalent Cases
• Liver Cirrhosis Etiology-specific Diagnosed Prevalent Cases

Liver Cirrhosis Treatment Market 

Cirrhosis treatment strategies differ depending on the disease stage and underlying etiology. The goals of liver cirrhosis treatment for compensated cirrhosis are to slow, halt, or reverse fibrosis progression and to prevent decompensation events, whereas the focus for decompensated cirrhosis is to prevent further decompensation and death (e.g., by improving liver function) and to treat complications related to portal hypertension. Importantly, any treatment plan for cirrhotic patients should not raise the risk of hepatocellular carcinoma (HCC) and, in accordance with FDA guidelines, should ultimately enhance how a patient feels, functions, or survives.

Except for low-dose aspirin in patients whose cardiovascular disease severity exceeds the severity of cirrhosis, analgesics such as nonsteroidal anti-inflammatory medications are contraindicated. Opiates should be used with caution or avoided entirely since they can cause or worsen hepatic encephalopathy. Tramadol and topical lidocaine patches are both safe in modest doses. Acetaminophen is helpful and safe in people with liver problems, but they should avoid consuming alcohol.

The US Food and Drug Administration has approved Epclusa for the treatment of adult patients with chronic hepatitis C virus (HCV) with and without cirrhosis. Epclusa is a fixed-dose combination tablet that contains sofosbuvir, a drug approved in 2013, and velpatasvir (generic), a novel treatment that is the first to treat all six primary types of HCV.

To know more about liver cirrhosis treatment, visit @ Liver Cirrhosis Treatment Drugs 

Key Liver Cirrhosis Therapies and Companies

• Resmetirom (MGL-3196): Madrigal Pharmaceuticals, Inc.
• Belapectin (GR-MD-02): Galectin Therapeutics Inc.
• Albutein: Grifols Therapeutics LLC
• Seladelpar: CymaBay Therapeutics
• Efruxifermin (AKR-001): Akero Therapeutics, Inc.
• Aldafermin (NGM282): NGM Biopharmaceuticals, Inc.
• Semaglutide, Cilofexor, and Firsocostat: Gilead Sciences/Novo Nordisk A/S
• Semaglutide, NNC0194-0499: Novo Nordisk A/S
• HepaStem: Cellaion/Promethera Therapeutics
• LPCN 1148: Lipocine Inc.
• BMS-986263: Bristol Myers Squibb
• PRI-724: Prism Pharma, Ohara Pharmaceutical
• ADR-001: Shionogi/Rohto

Learn more about the FDA-approved drugs for liver cirrhosis @ Drugs for Liver Cirrhosis Treatment 

Liver Cirrhosis Market Dynamics

The liver cirrhosis market is expected to change in the coming years. With no approved medications for severe hepatic cirrhosis, strategies to stabilize or reverse fibrotic disease progression are urgently needed. The US Food and Drug Administration has approved various drugs to treat CHB, CHC, and PBC, but none specifically target cirrhosis patients. However, there is rising anticipation that new drugs that favor the disease's natural course will be available in the liver cirrhosis market within the next 3-5 years.

The liver cirrhosis companies and academics are working to assess challenges and seek opportunities that could influence liver cirrhosis R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition. Various companies are involved in developing liver cirrhosis therapies. Moreover, the anticipated introduction of emerging therapies with improved efficacy and a further improvement in the early detection of the condition are expected to drive the growth of the liver cirrhosis market in the 7MM.

However, certain factors may affect the growth of the liver cirrhosis market. The liver cirrhosis market growth may be offset by unaffordable pricing, market access and reimbursement issues, and a shortage of healthcare specialists. In addition, the undiagnosed, unreported cases and the unawareness about the disease may also impact the liver cirrhosis market growth.

Scope of the Liver Cirrhosis Market Report

• Therapeutic Assessment: Liver Cirrhosis current marketed and emerging therapies
• Liver Cirrhosis Market Dynamics: Attribute Analysis of Emerging Liver Cirrhosis Drugs
• Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
• Unmet Needs, KOL's Views, Analyst's Views, Liver Cirrhosis Market Access and Reimbursement

Discover more about liver cirrhosis drugs in development @ Liver Cirrhosis Clinical Trials

Table of Contents

Related Reports

Liver Cirrhosis Pipeline

Liver Cirrhosis Pipeline Insight – 2023 report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the key liver cirrhosis companies, including CymaBay Therapeutics, Mirum Pharmaceuticals, Pharmicell Co., Ltd., Can-Fite BioPharma, Genfit, SHIONOGI & Co., COUR Pharmaceutical, Zydus Therapeutics Inc, Genkyotex SA, Gannex Pharma Co., Ltd., Novartis, HighTide Biopharma Pty Ltd, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GlaxoSmithKline, Ohara Pharmaceutical, Pliant Therapeutics, MYR Pharmaceuticals, among others.

Liver Cirrhosis Epidemiology Forecast

Liver Cirrhosis Epidemiology Forecast – 2032 report delivers an in-depth understanding of the disease, historical and forecasted liver cirrhosis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Nonalcoholic Steatohepatitis Market

Nonalcoholic Steatohepatitis Market Insight, Epidemiology, and Market Forecast – 2032 report delivers an in-depth understanding of the market trends, market drivers, market barriers, and key nonalcoholic steatohepatitis companies, including Madrigal Pharmaceuticals, Intercept Pharmaceuticals, Cirius Therapeutics, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Poxel SA, AngioLab, Pfizer, Lipocine, Inc., CytoDyn, Inc., Alnylam Pharmaceuticals, Inc., Mitsubishi Tanabe Pharma, Chemomab Therapeutics, NuSirt Biopharma, HK inno. N, Kowa Pharmaceutical, Ionis Pharmaceuticals, NorthSea Therapeutics, Rivus Pharmaceuticals, Hanmi Pharmaceutical, among others.

Non-Alcoholic Fatty Liver Disease Market

Non-Alcoholic Fatty Liver Disease Market Insights, Epidemiology, and Market Forecast – 2032 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key non-alcoholic fatty liver disease companies including BeiGene, Inventiva Pharma, Cirius Therapeutics, Inventiva Pharma, Novo Nordisk, Galmed Pharmaceuticals, AstraZeneca, Galectin Therapeutics, Viking Therapeutics, Dr. Falk Pharma GmbH, Sagimet Biosciences, Eli Lilly and Company, Terns Pharmaceuticals, Sinew Pharma, Novartis Pharmaceuticals, Afimmune, Poxel SA, AngioLab, Pfizer, Oramed Pharmacetuicals, Can Fite Biopharma, among others.

About DelveInsight

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

Contact Us

Shruti Thakur 
info@delveinsight.com
+1(919)321-6187
www.delveinsight.com 

Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg